Founder & Managing Partner
and access,
Dr. Ben-Joseph is a Founder and Managing Partner at Outcome Capital. He brings a unique combination of executive, entrepreneurial, scientific and transactional expertise to Outcome Capital. He is passionate about assisting cutting-edge life sciences companies in enhancing their clinical and strategic value and developing a path to a successful liquidity. Dr. Ben-Joseph served in numerous entrepreneurial and operational roles in life sciences companies. More recently, he was a Co-Founder and Director of ELIOS Vision, a commercial-stage developer of ExTra Laser trabeculotomy for the treatment of glaucoma, and served as a Director of XableCath, a clinical-stage medical device innovator developing cost-effective treatment options for peripheral and cardiovascular disease. Dr. Ben-Joseph also served as Mentor at the MIT Innovation Fund, assisting young entrepreneurs in defining market-aligned paths for novel technologies. Before founding Outcome Capital, Dr. Ben-Joseph was Managing Director at Boston Equity Advisors, a boutique investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector. Prior to that, Dr. Ben-Joseph was an Executive-in-Residence at Oxford Bioscience Partners, a life sciences venture capital firm, and CEO and Co-Founder of Caliber Therapeutics, a company engaged in the development of catheter-based drug delivery products for the treatment of atherosclerotic diseases. His past managerial and entrepreneurial positions also include President and CEO at Deep Vein Medical, an early-stage medtech company dedicated to treating deep venous reflux in patients suffering from chronic venous insufficiency; President and CEO of X-Cell Medical, a clinical-stage drug/device convergence company engaged in the development of novel stent-based anti-restenotic drugs; President of Ester Neurosciences, a clinical-stage biotech company engaged in the development of novel compounds for the treatment of neurological diseases; and co-founder and CEO of Biolight Phototherapy, a company engaged in the development of laser-based medical devices for the treatment of dermatological disorders and allergies. His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, Visiting Associate Professor at Tokushima University in Japan and Visiting Scientist at Pfizer. Dr. Ben-Joseph has published numerous peer-reviewed scientific papers and industry publications and has received awards and scholarships including the Krebs Memorial Scholarship awarded by the Biochemical Society, Overseas Research Student Award given by the Committee of Vice-Chancellors and Principals of the Universities of the United Kingdom, and a Post-Doctoral Award from the American Brain Tumor Association. He has been frequently invited to speak at industry and academic conferences and to share his expertise in life science entrepreneurship, innovation and commercialization. Dr. Ben-Joseph graduated with Honors from Imperial College London and received his Ph.D. from the University of Cambridge. He completed his post-doctoral training at the University of Michigan and received an MBA magna cum laude from the University of Bradford. He is a FINRA Securities Representative holding Series 7, 63 and 79 registration and a Registered Securities Principal holding a Series 24.
